Menu
Partner
Andrew Roper is a partner in Haug Partners’ New York office. His practice focuses on high-stakes patent litigation, with particular strength in life sciences disputes, Federal Circuit appeals, and post-grant proceedings before the PTAB. He has extensive experience litigating complex pharmaceutical and biologics patents.
Known for combining deep technical fluency with disciplined fact development, Andrew excels at distilling complex scientific records into clear, persuasive case theories. He is particularly effective in expert-driven disputes and has repeatedly shaped case outcomes turning on competing expert testimony, technical credibility, and close scrutiny of the evidentiary record. In one recent matter, he defended the full term of patent and regulatory exclusivity for a $2.6 billion-per-year product, guiding case strategy and securing key admissions that led the court to discount the testimony of the primary opposing technical experts.
Andrew regularly handles trial and summary judgment matters across a wide range of technologies, including compounds, formulations, polymorphs, methods of treatment, pharmacokinetics and pharmacodynamics, and manufacturing processes. His PTAB experience includes successful defenses of patent validity via both trial and institution denial in technically complex proceedings.
In addition to litigation, Andrew provides strategic intellectual property counseling, including FDA-related guidance on regulatory exclusivity and Orange Book considerations, and due diligence support for transactions. His experience also spans medical device matters, including disputes involving source code and AI-related technologies.
Andrew holds a B.S.E. in Chemical Engineering from Case Western Reserve University and a J.D. from the University of Virginia, and is a registered patent attorney. He serves as Programs Committee co-chair of the New York Intellectual Property Law Association.
